C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/19 (2006.01) A61K 31/7088 (2006.01) A61K 38/19 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61P 17/00 (2006.01) A61P 19/00 (2006.01) A61P 31/18 (2006.01) A61P 37/06 (2006.01) C07K 14/52 (2006.01) C07K 16/28 (2006.01) C07K 19/00 (2006.01) C12N 15/12 (2006.01) C12N 15/13 (2006.01) C12N 15/63 (2006.01) C12P 21/02 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2421842
The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.
La présente invention concerne l'utilisation d'une construction d'anticorps et/ou de chimiokine qui se lie au récepteur de la chimiokine pour la préparation d'une composition pharmaceutique destinée à éliminer des cellules infectées de manière latente avec un virus d'immunodéficience d'un primate. Elle concerne également l'utilisation d'une construction d'anticorps et/ou de chimiokine qui se lie au récepteur de la chimiokine pour la préparation d'une composition pharmaceutique destinée au traitement, à la prévention et/ou à l'atténuation de maladies rénales inflammatoires, de maladies entériques inflammatoires, de la sclérose en plaques, de maladies de la peau, du diabète, ou du rejet de greffons. L'invention concerne aussi des constructions d'anticorps et/ou des constructions de chimiokine. La construction d'anticorps comprend un site de liaison du récepteur 5 de la chimiokine et un site de liaison pour CD3; et la construction de chimiokine comprend RANTES et une toxine. L'invention concerne des polynucléotides codant lesdites constructions d'anticorps et/ou de chimiokine, et des vecteurs et hôtes comprenant lesdites molécules d'acide nucléique. L'invention concerne des compositions comprenant ces constructions d'anticorps, ces constructions de chimiokine, ces polynucléotides, ces vecteurs et/ou hôtes, lesdites compositions étant, de préférence, des compositions pharmaceutiques. On décrit l'utilisation des constructions d'anticorps, des constructions de chimiokine, des polynucléotides, des hôtes et/ou vecteurs de préparation d'une composition pharmaceutique, et des méthodes de traitement, de prévention et/ou d'atténuation d'un trouble immunologique ou d'élimination de cellules infectées de manière latente avec un virus d'immunodéficience d'un primate, tel que le VIH-1. L'invention concerne en outre un nécessaire comprenant les composés de l'invention.
Mack Matthias
Schloendorff Detlef
Spring Michael
Goudreau Gage Dubuc
Micromet Ag
LandOfFree
Antibody and/or chemokine constructs which bind to a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody and/or chemokine constructs which bind to a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody and/or chemokine constructs which bind to a... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1449925